Intrinsic Imaging announced that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with advanced squamous cell carcinoma (SCC). Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and imaging charter development, site qualification, site training and management, image transfer, blinding and processing of images acquired by computed tomography (CT) or magnetic resonance imaging (MRI). Subsequently, study treatment response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation criteria. According to ClinicalTrials.gov, there are currently nine Phase II clinical trials listed for SCC.
